Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Aug 1.

Published in final edited form as: Neurobiol Dis. 2011 Apr 15;43(2):330–337. doi: 10.1016/j.nbd.2011.03.022

Using the Gal4-UAS system, (A) eLav-Gal4 flies and UAS-p35 Drosophila were bred with balancer flies to generate eLav-p35 flies. ELav-p35 Drosophila targeted expression of p35, a baculovirus anti-apoptotic protein, specifically in neurons. Expression of the caspase-inhibitor p35 in Drosophila brain prevented cisplatin induced apoptosis, lethality and climbing inhibition. ELav-p35 Drosophila were treated with or without 100μg/ml cisplatin and immunotstained for p35 expression and caspase 3 activation. p35 was not expressed in (B) wild type brain (Wt) but was expressed in (C) eLav-p35 brain neurons as indicated by co-localization of p35 (green) with eLav staining (red). Expression of p35 prevented caspase 3 activation in eLav-p35 brains treated (D) without or (E) with cisplatin. In Ovaries, no expression of p35 was observed in either (F) Wt or (G) eLav-p35 oocytes and no caspase 3 staining was observed in (H) control eLav-p35 oocytes. Cisplatin treatment induced positive active caspase 3 staining in (I) eLav-p35 oocytes. p35 expression in neurons improved (J) fly survival and prevented (K) climbing inhibition induced by cisplatin treatment. Wild type (Wt) and eLav-p35 (p35) flies were treated with 100μg/ml cisplatin. Cisplatin reduced fly survival and inhibited climbing ability in wild type flies (Wt+Cis). Survival was slightly improved (p=0.0347) and climbing inhibition significant improved (p<0.0001) by the expression of neuronal p35 in cisplatin treated eLav-p35 flies (p35+Cis).

Using the Gal4-UAS system, (A) eLav-Gal4 flies and UAS-p35 Drosophila were bred with balancer flies to generate eLav-p35 flies. ELav-p35 Drosophila targeted expression of p35, a baculovirus anti-apoptotic protein, specifically in neurons. Expression of the caspase-inhibitor p35 in Drosophila brain prevented cisplatin induced apoptosis, lethality and climbing inhibition. ELav-p35 Drosophila were treated with or without 100μg/ml cisplatin and immunotstained for p35 expression and caspase 3 activation. p35 was not expressed in (B) wild type brain (Wt) but was expressed in (C) eLav-p35 brain neurons as indicated by co-localization of p35 (green) with eLav staining (red). Expression of p35 prevented caspase 3 activation in eLav-p35 brains treated (D) without or (E) with cisplatin. In Ovaries, no expression of p35 was observed in either (F) Wt or (G) eLav-p35 oocytes and no caspase 3 staining was observed in (H) control eLav-p35 oocytes. Cisplatin treatment induced positive active caspase 3 staining in (I) eLav-p35 oocytes. p35 expression in neurons improved (J) fly survival and prevented (K) climbing inhibition induced by cisplatin treatment. Wild type (Wt) and eLav-p35 (p35) flies were treated with 100μg/ml cisplatin. Cisplatin reduced fly survival and inhibited climbing ability in wild type flies (Wt+Cis). Survival was slightly improved (p=0.0347) and climbing inhibition significant improved (p<0.0001) by the expression of neuronal p35 in cisplatin treated eLav-p35 flies (p35+Cis).